Speaker Profile

Ph.D., Professor, Center Director, Arizona State University

Biography
Dr. Rosa Krajmalnik-Brown is a Professor at the School of Sustainable Engineering and The Built Environment and the Director of the Biodesign Center for Health Through Microbiomes at Arizona State University. Her research focuses on understanding microbe-microbe, microbe-environment, and microbe-host interactions. Her research team was the first one to describe gut microbiome changes after gastric bypass surgery, and the first research team to design and implement a successful microbiota-based therapy to improve gastrointestinal and autism symptoms. Her interests and research also include bioremediation, the use of microbial systems for bioenergy production, and the human intestinal microbial ecology and its relationship to obesity, metabolism, and autism.

Talk
Microbiota Transfer Therapy for Autism
Recent studies in human cohorts and mouse models have shown links between gut microbiota and autism. We pioneered an autism-targeted open-label clinical trial of microbiota modification. Gastro-intestinal symptoms and behavior improved significantly, and most improvements remained two years after treatment.


 Session Abstract – PMWC 2022 Silicon Valley


Understanding mechanism of action and translating microbiome science into commercially viable therapeutics remains the biggest challenge in this emerging field. With that said, pharma and biotech across many different therapeutic indications and modalities are united in this global effort to bring novel microbiome-based therapies and diagnostics into the clinical domain. This session will include some of the most impactful and promising areas of the Microbiome field and panel discussions on the challenges for faster adoption.

Sessions:

Microbiome and Cancer
Jennifer Wargo, MD Anderon
Sandrine Miller-Montgomery, UCSD

The Gut/Brain Microbiome
Mary Conrad, Axial Biotherapeutics
Chris Reyes, Bloom Science
Rosa Krajmalnik-Brown, Arizona State University

The Role of the Human Gut Microbiome on Various Diseases
Colleen Cutcliffe, Pendulum Therapeutics
Tor Savidge, Baylor College of Medicine
Nikole Kimes, Siolta Therapeutics

Pharma Drug Development
Karim Dabbagh, Second Genome
Ethan Grant, Gilead

Direct-To-Consumer Testing/Technologies
Kiran Krishnan, Microbiome Labs
Nathan Price, Onegevity

Regulatory Perspective
Scott Jackson, NIST

Investment Perspective